Not at all, people with Vitiligo have very little to help them. The initial results seen from Scenesse are phenomenal, I see no reason not to expect fantastic P3 results and quick approval for vitiligo. The phase three trial will be completed quite fast, they're actively recruiting now so I'd be expecting updates soon. First patient in the trial was treated in October of last year... commercialisation is close imo
More data from the XP trials should come soon as well, not that XP is a very large market (still an additional market for CUV to be a monopoly player in), but most importantly the data will help prove the importance of this drug in sun protection etc
- Forums
- ASX - By Stock
- CUV
- Ssilverchair
Ssilverchair, page-6
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.70 |
Change
0.120(0.88%) |
Mkt cap ! $685.8M |
Open | High | Low | Value | Volume |
$13.53 | $13.76 | $13.42 | $747.9K | 54.81K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 233 | $13.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.71 | 19 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 13.500 |
1 | 1000 | 13.480 |
2 | 2007 | 13.400 |
2 | 8864 | 13.380 |
1 | 500 | 13.330 |
Price($) | Vol. | No. |
---|---|---|
13.880 | 300 | 1 |
13.890 | 742 | 1 |
13.990 | 500 | 1 |
14.200 | 1943 | 2 |
14.230 | 300 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online